These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19995970)

  • 1. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.
    Schonthaler HB; Huggenberger R; Wculek SK; Detmar M; Wagner EF
    Proc Natl Acad Sci U S A; 2009 Dec; 106(50):21264-9. PubMed ID: 19995970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.
    Kunstfeld R; Hirakawa S; Hong YK; Schacht V; Lange-Asschenfeldt B; Velasco P; Lin C; Fiebiger E; Wei X; Wu Y; Hicklin D; Bohlen P; Detmar M
    Blood; 2004 Aug; 104(4):1048-57. PubMed ID: 15100155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis.
    Hvid H; Teige I; Kvist PH; Svensson L; Kemp K
    Int Immunol; 2008 Aug; 20(8):1097-106. PubMed ID: 18579711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposing roles of endothelial and leukocyte-expressed IL-7Rα in the regulation of psoriasis-like skin inflammation.
    Vranova M; Friess MC; Haghayegh Jahromi N; Collado-Diaz V; Vallone A; Hagedorn O; Jadhav M; Willrodt AH; Polomska A; Leroux JC; Proulx ST; Halin C
    Sci Rep; 2019 Aug; 9(1):11714. PubMed ID: 31406267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microvascular changes in relation to inflammation and epidermal hyperplasia in chronic cutaneous lesions of psoriasis vulgaris.
    Výbohová D; Adamicová K; Mellová Y; Hešková G
    Histol Histopathol; 2017 May; 32(5):461-470. PubMed ID: 27633550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tranilast could has potential therapeutic value in the treatment of psoriasis.
    Mansouri K; Motlagh HR; Keshavarz M
    Med Hypotheses; 2011 Feb; 76(2):217-9. PubMed ID: 21030156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
    Canavese M; Altruda F; Ruzicka T; Schauber J
    J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
    Liu JH; Wu HH; Zhao YK; Wang F; Gao Q; Luo DQ
    Curr Vasc Pharmacol; 2018; 16(5):510-521. PubMed ID: 28982338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment.
    Moustou AE; Alexandrou P; Stratigos AJ; Giannopoulou I; Vergou T; Katsambas A; Antoniou C
    An Bras Dermatol; 2014; 89(6):891-7. PubMed ID: 25387493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, pathological and immunological features of psoriatic-like lesions affecting keratin 14-vascular endothelial growth factor transgenic mice.
    Canavese M; Altruda F; Silengo L; Castiglioni V; Scanziani E; Radaelli E
    Histol Histopathol; 2011 Mar; 26(3):285-96. PubMed ID: 21210341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.
    Xia YP; Li B; Hylton D; Detmar M; Yancopoulos GD; Rudge JS
    Blood; 2003 Jul; 102(1):161-8. PubMed ID: 12649136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells.
    Wang Y; Mao Y; Zhang J; Shi G; Cheng L; Lin Y; Li Y; Zhang X; Zhang Y; Chen X; Deng J; Su X; Dai L; Yang Y; Zhang S; Yu D; Wei Y; Deng H
    J Cell Mol Med; 2018 Feb; 22(2):1014-1025. PubMed ID: 29193791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis.
    Yan HX; Wang Y; Yang XN; Fu LX; Tang DM
    Mol Med Rep; 2013 Aug; 8(2):434-8. PubMed ID: 23732650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IL-17A signalling in psoriasis and associated bone loss.
    Uluçkan Ö; Wagner EF
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):17-20. PubMed ID: 27586798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production.
    Teng X; Hu Z; Wei X; Wang Z; Guan T; Liu N; Liu X; Ye N; Deng G; Luo C; Huang N; Sun C; Xu M; Zhou X; Deng H; Edwards CK; Chen X; Wang X; Cui K; Wei Y; Li J
    J Immunol; 2014 Feb; 192(4):1815-23. PubMed ID: 24453242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.
    Schwager S; Renner S; Hemmerle T; Karaman S; Proulx ST; Fetz R; Golding-Ochsenbein AM; Probst P; Halin C; Neri D; Detmar M
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.
    Ma L; Xue H; Qi R; Wang Y; Yuan L
    J Transl Med; 2018 Mar; 16(1):59. PubMed ID: 29523162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
    Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
    Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Halin C; Fahrngruber H; Meingassner JG; Bold G; Littlewood-Evans A; Stuetz A; Detmar M
    Am J Pathol; 2008 Jul; 173(1):265-77. PubMed ID: 18535184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF.
    Man XY; Yang XH; Cai SQ; Bu ZY; Zheng M
    J Cell Mol Med; 2008 Apr; 12(2):649-60. PubMed ID: 18419602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.